Evaluation of Safety After Intracordal Basic Fibroblast Growth Factor Injection

IF 2.4 4区医学 Q1 AUDIOLOGY & SPEECH-LANGUAGE PATHOLOGY

Journal of Voice Pub Date : 2025-09-01 DOI:10.1016/j.jvoice.2023.03.007

Tomohiro Hasegawa , Retsu Fujita , Daigo Komazawa , Ujimoto Konomi , Mayu Hirosaki , Yusuke Watanabe

{"title":"Evaluation of Safety After Intracordal Basic Fibroblast Growth Factor Injection","authors":"Tomohiro Hasegawa , Retsu Fujita , Daigo Komazawa , Ujimoto Konomi , Mayu Hirosaki , Yusuke Watanabe","doi":"10.1016/j.jvoice.2023.03.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Although there are many reports of voice improvement with intracordal trafermin (a basic fibroblast growth factor) injections under local anesthesia, few papers have documented the safety of trafermin. Therefore, we aimed to investigate whether trafermin is safer than control drugs (triamcinolone acetonide) early after intracordal injection under local anesthesia.</div></div><div><h3>Methods</h3><div><span>We conducted a retrospective review from the medical records of patients who underwent intracordal injection with trafermin and </span>triamcinolone acetonide under local anesthesia at our institution. Early postinjective complications were defined as changes in vital signs and chief complaints early after intracordal injection.</div></div><div><h3>Results</h3><div><span>A total of 699 and 297 patients underwent intracordal injection under local anesthesia with trafermin and triamcinolone acetonide, respectively. Of these, 227 and 130 patients had early postinjective complications with trafermin and triamcinolone acetonide, retrospectively. The most common complications occurring with trafermin was increased blood pressure in 39 cases (5.58%): 17 cases (2.43%) of blood pressure increase of ≥20 mm Hg. Other complications included pharyngeal discomfort in 37 (5.29%), </span>lightheadedness<span> in 33 (4.72%), and phlegm discharge in 29 (4.15%). Triamcinolone acetonide caused pharyngeal discomfort in 28 patients (9.43%), phlegm discharge in 17 patients (5.72%), lightheadedness<span> in 12 patients (4.04%), sore throat in 11 patients (3.70%), increased blood pressure in 10 patients (3.37%): 7 cases (2.36%) of blood pressure increase of ≥20 mm Hg, and dizziness in seven patients (2.36%). Statistical analysis of the complications between trafermin and triamcinolone acetonide showed no significant differences.</span></span></div></div><div><h3>Conclusions</h3><div>The proportion of early postinjective complications from intracordal injection of trafermin is no significant difference in that of triamcinolone acetonide. The results suggest that the early postinjective complications are not due to the drug action of trafermin, but rather to complications from the intracordal injection procedures. Intracordal trafermin injection may be safe in the short term.</div></div>","PeriodicalId":49954,"journal":{"name":"Journal of Voice","volume":"39 5","pages":"Pages 1419.e29-1419.e37"},"PeriodicalIF":2.4000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Voice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0892199723001005","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"AUDIOLOGY & SPEECH-LANGUAGE PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Although there are many reports of voice improvement with intracordal trafermin (a basic fibroblast growth factor) injections under local anesthesia, few papers have documented the safety of trafermin. Therefore, we aimed to investigate whether trafermin is safer than control drugs (triamcinolone acetonide) early after intracordal injection under local anesthesia.

Methods

We conducted a retrospective review from the medical records of patients who underwent intracordal injection with trafermin and triamcinolone acetonide under local anesthesia at our institution. Early postinjective complications were defined as changes in vital signs and chief complaints early after intracordal injection.

Results

A total of 699 and 297 patients underwent intracordal injection under local anesthesia with trafermin and triamcinolone acetonide, respectively. Of these, 227 and 130 patients had early postinjective complications with trafermin and triamcinolone acetonide, retrospectively. The most common complications occurring with trafermin was increased blood pressure in 39 cases (5.58%): 17 cases (2.43%) of blood pressure increase of ≥20 mm Hg. Other complications included pharyngeal discomfort in 37 (5.29%), lightheadedness in 33 (4.72%), and phlegm discharge in 29 (4.15%). Triamcinolone acetonide caused pharyngeal discomfort in 28 patients (9.43%), phlegm discharge in 17 patients (5.72%), lightheadedness in 12 patients (4.04%), sore throat in 11 patients (3.70%), increased blood pressure in 10 patients (3.37%): 7 cases (2.36%) of blood pressure increase of ≥20 mm Hg, and dizziness in seven patients (2.36%). Statistical analysis of the complications between trafermin and triamcinolone acetonide showed no significant differences.

Conclusions

The proportion of early postinjective complications from intracordal injection of trafermin is no significant difference in that of triamcinolone acetonide. The results suggest that the early postinjective complications are not due to the drug action of trafermin, but rather to complications from the intracordal injection procedures. Intracordal trafermin injection may be safe in the short term.

查看原文本刊更多论文

鞘内注射碱性成纤维细胞生长因子的安全性评价

目的：虽然有许多关于局部麻醉下脊髓内注射曲弗明（一种基本成纤维细胞生长因子）改善语音的报道，但很少有论文证明曲弗明的安全性。因此，我们的目的是探讨在局麻下脊髓内注射后早期使用曲安奈德是否比对照药物曲安奈德更安全。方法回顾性分析本院局麻下行曲曲明和曲安奈德脊髓内注射的患者病历。注射后早期并发症定义为脊髓内注射后早期生命体征和主诉的改变。结果局麻下分别注射曲福明699例和曲安奈德297例。回顾性分析，其中227例和130例患者有曲安奈德和曲安奈德的早期注射后并发症。曲弗明最常见的并发症是血压升高39例（5.58%），血压升高≥20 mm Hg 17例（2.43%），其他并发症包括咽部不适37例（5.29%），头晕33例（4.72%），咳痰29例（4.15%）。曲安奈德引起咽部不适28例（9.43%），咳痰17例（5.72%），头晕12例（4.04%），咽痛11例（3.70%），血压升高10例（3.37%），血压升高≥20 mm Hg 7例（2.36%），头晕7例（2.36%）。曲安奈德与曲安奈德并发症统计分析差异无统计学意义。结论脊髓内注射曲安奈德与曲曲安奈德早期注射后并发症的比例无显著差异。结果表明，早期注射后并发症不是由于曲弗明的药物作用，而是由于鞘内注射过程的并发症。卵索内注射曲霉素在短期内可能是安全的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Voice 医学-耳鼻喉科学

CiteScore

4.00

自引率

13.60%

发文量

395

审稿时长

59 days

期刊介绍： The Journal of Voice is widely regarded as the world''s premiere journal for voice medicine and research. This peer-reviewed publication is listed in Index Medicus and is indexed by the Institute for Scientific Information. The journal contains articles written by experts throughout the world on all topics in voice sciences, voice medicine and surgery, and speech-language pathologists'' management of voice-related problems. The journal includes clinical articles, clinical research, and laboratory research. Members of the Foundation receive the journal as a benefit of membership.